Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…
McAlinden Research PartnersDecember 8, 2022
The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…
McAlinden Research PartnersSeptember 29, 2022
Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…
McAlinden Research PartnersMay 23, 2022
Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…
McAlinden Research PartnersSeptember 8, 2021
A wealth of new data from several leading genomics firms have launched stocks in the sector higher in the fourth…
McAlinden Research PartnersDecember 22, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…
McAlinden Research PartnersJune 16, 2020
Though many sectors have been whacked by the Coronavirus-related hurdles in 2020, research and development of the gene editing technology…
McAlinden Research PartnersMay 13, 2020
New research on CRISPR techniques that could provide treatments and improved diagnostics for several major viruses and other medical conditions…
McAlinden Research PartnersNovember 13, 2019
